Navigation Links
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Date:9/18/2007

ported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (5%) and neutropenia (3%). Fifty percent of patients reported serious adverse events. The most commonly reported serious adverse events were pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%).

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is http://www.millennium.com .

This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development effo
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02316671/Global-Orthopedic-Soft-Tissue-Repair-Devices-Market-2014-2018.html ... soft tissues are the mass of cells that ... types of orthopedic soft tissues such as tendons, ...
(Date:8/27/2014)... 2014 Decision Resources Group finds that the ... Memphis health system and hospital sector in ... rivals Methodist Le Bonheur Healthcare and Baptist Memorial Health ... patient care. In addition, a national contract recently signed ... plan enrollment in the Memphis ...
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02316644/Global-Heart-Valve-Repair-and-Replacement-Market-2014-2018.html ... are structures in the human heart which control ... A person affected with heart valve diseases such ...
Breaking Medicine Technology:Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 3Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 5Memphis-area Health Systems Turn Attention to Clinical Integration 2Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4
... , PITTSBURGH, Dec. 22 Mylan Inc. (Nasdaq: MYL ... received tentative approval from the U.S. Food and Drug Administration ... for its New Drug Application (NDA) for Efavirenz Tablets, 50 ... in tablet form were developed by Matrix for use in ...
... , , , , , , CAPUA, Italy, Dec. 22 ... an agreement with Laboratoires Mayoly Spindler, Chatou Cedex, France, for ... process development and commenced cGMP manufacture of the Mayoly Spindler ... BioSolutions manufactures the lipase compound at its microbial fermentation facility ...
Cached Medicine Technology:Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories' New Drug Application (NDA) for Efavirenz Tablets 2DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 2DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 3DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 4
(Date:8/27/2014)... The National League for Nursing is ... RN, FAAN, became the inaugural director of the ... the Science of Nursing Education , effective August 11. ... NLN Home for Transformative Excellence, established with the League’s ... , Under Dr. Dennis’s leadership, the NLN/Chamberlain Center ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 Delta, a ... recently added several practical Cat D7R Dozers to its ... company’s senior spokesman has announced that all these items ... this promotion is to expand Delta’s market share in ... proud to launch the special offer; he has much ...
(Date:8/27/2014)... Lake Worth, FL (PRWEB) August 27, 2014 ... they are now a sponsor for Florida Mental Health ... to the benefits the new sponsorship is sure to ... meeting the professional needs of Florida’s licensed mental health ... division of the American Counseling Association (ACA) and since ...
(Date:8/27/2014)... August 27, 2014 The New York ... is holding free events about “ Sexuality & Intimacy ... Treston. These straightforward and entertaining discussions are for mature ... Mobility (501 Concord Avenue, Mamaroneck, NY) and October 7 ... Bethpage, NY). , The New York Mobility Club ...
(Date:8/27/2014)... The American College of ... management and treatment of pulmonary arterial hypertension (PAH) ... in Adults: CHEST Guideline, in the journal CHEST. ... and provide the latest and most accurate treatment ... Association (PHA) – the country’s leading pulmonary ...
Breaking Medicine News(10 mins):Health News:Betty Pierce Dennis to Lead NLN/Chamberlain College of Nursing Center for the Advancement of the Science of Nursing Education 2Health News:Betty Pierce Dennis to Lead NLN/Chamberlain College of Nursing Center for the Advancement of the Science of Nursing Education 3Health News:Betty Pierce Dennis to Lead NLN/Chamberlain College of Nursing Center for the Advancement of the Science of Nursing Education 4Health News:Reliable Supplier Delta Adds New Items To Its Used Bulldozer Collection 2Health News:Millennium Treatment Group Sponsors Florida Mental Health Counselors Association 2Health News:Bussani Mobility Sponsors New York Mobility Club Meetings September 9 & October 7 for People with Disabilities, Sexuality & Intimacy Discussed by Advocate Liz Treston 2Health News:Pulmonary Hypertension Association Endorses CHEST Guidelines for Treatment of Pulmonary Arterial Hypertension in Adults 2
... Spain throughout the second half of the twentieth century. ... factors such as the advice of healthcare professionals, longer ... her level of education. "Up until not ... but things have changed in the second half of ...
... HealthDay Reporter , THURSDAY, Sept. 29 (HealthDay News) -- ... the globe, new research suggests that folks seem to awaken ... regardless of where they live. The novel study by ... people in 84 countries over two years, finding that work, ...
... IL Ben Franklin was right, at least on the healthy ... helped a cross-section of early-bird Australian youths keep slimmer and more ... the same amount of sleep. A study in the Oct. ... and wake times of 2,200 Australian participants, ages 9 to 16, ...
... , THURSDAY, Sept. 29 (HealthDay News) --,New genes associated ... large-scale analysis of genetic data related to the disease. ... six large databases for DNA data from about 10,000 ... In addition to validating results from previous research, ...
... has received a $750,000 grant from the Cleveland Foundation ... Stanley Hazen, M.D., Ph.D., will be ... spans a broad range of topics, from researching the ... identifying non-invasive testing for asthma. Recently, he published a ...
... in normal tissue may play a different role in colon ... researchers at the University of Illinois at Chicago College of ... skin and gut cells -- and in cancerous, but not ... the normal function of this protein in the gut, where ...
Cached Medicine News:Health News:Woman with a higher social standing and educational attainment breastfeed for longer 2Health News:Twitter Reflects World's Changing Moods 2Health News:Twitter Reflects World's Changing Moods 3Health News:Early to bed and early to rise -- study suggests it's keeping kids leaner 2Health News:Knockout of protein prevents colon tumor formation in mice 2
Ammonia reagent is used for the quantitative and enzymatic determination of ammonia in human plasma....
The Proteineer suite integrates powerful mass spectrometers with robotics and bioinformatics to deliver maximum productivity in high-throughput proteomics....
The new ProteomeX Workstation enables the rapid set up, execution and analysis of multidimensional LC/MS methods, providing you with the best possible technique to characterize your complex proteomic...
... functions over a wide range of ... delivering more thorough characterization than other ... the relative change in the distribution ... way to measure heterogeneity, stoichiometry and ...
Medicine Products: